Utilizing T-cell activation signals 1, 2 and 3 for tumor-infiltrating lymphocytes (TIL) expansion: the advantage over the sole use of interleukin-2 in cutaneous and uveal melanoma

In this study, we address one of the major critiques for TIL therapy - the time needed for proper expansion of a suitable product. We postulated that TCR activation in the first phase of expansion combined with an agonistic stimulation of CD137/4-1BB and IL-2 would favor preferential expansion of CD...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother
Main Authors: Tavera, René J., Forget, Marie-Andrée, Kim, Young Uk, Sakellariou-Thompson, Donastas, Creasy, Caitlin A., Bhatta, Ankit, Fulbright, Orenthial J., Ramachandran, Renjith, Thorsen, Shawne T., Flores, Esteban, Wahl, Arely, Gonzalez, Audrey M., Toth, Christopher, Wardell, Seth, Mansaray, Rahmatu, Radvanyi, Laszlo G., Gombos, Dan S., Patel, Sapna P., Hwu, Patrick, Amaria, Rodabe N., Bernatchez, Chantale, Haymaker, Cara
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6177302/
https://ncbi.nlm.nih.gov/pubmed/29757889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0000000000000230
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados